Board Committees

Audit Committee Position

Mitchell Chan

Mitchell Chan has more than 15 years of finance experience in the life sciences industry. Mr. Chan was previously the Chief Financial Officer at Viela Bio, where he was instrumental in supporting the company through capital raises with leading global healthcare investors. While at Viela Bio, he successfully raised over $750 million including an initial public offering in 2019. In 2021, he also led a merger transaction whereby Viela Bio was acquired by Horizon Therapeutics for $3.1 billion. Prior to Viela Bio, Mr. Chan served as the Director of Investor Relations for AstraZeneca, North America. Mr. Chan also held several roles of increasing responsibility at Genentech-Roche including in BioOncology Commercial Finance, R&D Finance, and Mergers & Acquisitions. Mr. Chan is the recipient of Executive Certifications from Stanford University, University of California (Haas), and University of Pennsylvania (Wharton) and earned his BSc in Biochemistry, MSc in Medical Biophysics, and MBA (Rotman School of Management) from the University of Toronto.

Chair

June Almenoff, MD, PhD

June Almenoff M.D., Ph.D., is an accomplished biopharma executive with close to 25 years of leadership experience. She brings expertise in R&D, commercialization, and executive leadership to this role. Dr. Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, which was acquired by Actavis for $1.2B. Furiex developed eluxadoline (Viberzi®), which was approved both in the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility.

Dr. Almenoff also served as Chief Medical Officer at RedHill Biopharma Ltd (Nasdaq: RDHL), where she was on the commercial executive team. She has deep expertise in many therapeutic and development areas having led or contributed to numerous submissions, product approvals and launches. Dr. Almenoff is on the investment advisory board of the Harrington Discovery Institute, a private venture philanthropy. She serves as a Board Director to Tenax Therapeutics, Inc. (Nasdaq: TENX). She previously served as a Board Director to Tigenix, which was acquired by Takeda, Kurome Therapeutics,  Brainstorm Cell Therapeutics (Nasdaq: BCLI), RDD Pharma (Chair), and Furiex Pharmaceuticals. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct Professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over 70 publications.

Member

Jonathan Goldman, MD

Jonathan Goldman, MD has 30 years of experience across life sciences as a CEO, Chief Medical Officer, investor, and senior executive. He currently serves as the CEO of Clinical ink, a global life science company that brings data, technology, and patient-centric research together. Prior to Clinical ink, Jonathan served as the CEO and a board member of Abzena and was previously the CEO of Aptuit. He has also held senior executive positions at ICON plc (Nasdaq: ICLR) and Point Biomedical Corp. in addition to holding appointments as Associate Clinical Professor of Medicine in the division of Cardiology at the University of California San Francisco, and as an Attending Cardiologist at the San Francisco Veterans Administration Medical Center. Jonathan trained in medicine at St. Bartholomew’s Hospital Medical College, in London and in cardiology at St. George’s Hospital Medical School, London. He received a BSc in immunology, as well as MBBS and MD degrees in medicine from the University of London, UK. He was awarded MBAs by Columbia University in New York and the University of California at Berkeley.

Member

Audit Committee Charter

Download

Mitchell Chan

Mitchell Chan has more than 15 years of finance experience in the life sciences industry. Mr. Chan was previously the Chief Financial Officer at Viela Bio, where he was instrumental in supporting the company through capital raises with leading global healthcare investors. While at Viela Bio, he successfully raised over $750 million including an initial public offering in 2019. In 2021, he also led a merger transaction whereby Viela Bio was acquired by Horizon Therapeutics for $3.1 billion. Prior to Viela Bio, Mr. Chan served as the Director of Investor Relations for AstraZeneca, North America. Mr. Chan also held several roles of increasing responsibility at Genentech-Roche including in BioOncology Commercial Finance, R&D Finance, and Mergers & Acquisitions. Mr. Chan is the recipient of Executive Certifications from Stanford University, University of California (Haas), and University of Pennsylvania (Wharton) and earned his BSc in Biochemistry, MSc in Medical Biophysics, and MBA (Rotman School of Management) from the University of Toronto.

June Almenoff, MD, PhD

June Almenoff M.D., Ph.D., is an accomplished biopharma executive with close to 25 years of leadership experience. She brings expertise in R&D, commercialization, and executive leadership to this role. Dr. Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, which was acquired by Actavis for $1.2B. Furiex developed eluxadoline (Viberzi®), which was approved both in the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility.

Dr. Almenoff also served as Chief Medical Officer at RedHill Biopharma Ltd (Nasdaq: RDHL), where she was on the commercial executive team. She has deep expertise in many therapeutic and development areas having led or contributed to numerous submissions, product approvals and launches. Dr. Almenoff is on the investment advisory board of the Harrington Discovery Institute, a private venture philanthropy. She serves as a Board Director to Tenax Therapeutics, Inc. (Nasdaq: TENX). She previously served as a Board Director to Tigenix, which was acquired by Takeda, Kurome Therapeutics,  Brainstorm Cell Therapeutics (Nasdaq: BCLI), RDD Pharma (Chair), and Furiex Pharmaceuticals. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct Professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over 70 publications.

Jonathan Goldman, MD

Jonathan Goldman, MD has 30 years of experience across life sciences as a CEO, Chief Medical Officer, investor, and senior executive. He currently serves as the CEO of Clinical ink, a global life science company that brings data, technology, and patient-centric research together. Prior to Clinical ink, Jonathan served as the CEO and a board member of Abzena and was previously the CEO of Aptuit. He has also held senior executive positions at ICON plc (Nasdaq: ICLR) and Point Biomedical Corp. in addition to holding appointments as Associate Clinical Professor of Medicine in the division of Cardiology at the University of California San Francisco, and as an Attending Cardiologist at the San Francisco Veterans Administration Medical Center. Jonathan trained in medicine at St. Bartholomew’s Hospital Medical College, in London and in cardiology at St. George’s Hospital Medical School, London. He received a BSc in immunology, as well as MBBS and MD degrees in medicine from the University of London, UK. He was awarded MBAs by Columbia University in New York and the University of California at Berkeley.

Compensation Committee Position

Aaron Kantoff

Aaron Kantoff is a founder and Managing Partner of Scion Life Sciences. He has spent over a decade specializing in founding, building and investing in biotech companies. Aaron was a founding board member of Tourmaline Bio (Nasdaq: TRML), Centessa Pharmaceuticals (Nasdaq: CNTA), and RayzeBio (Nasdaq: RYZB), which was recently acquired by Bristol Myers Squibb (NYSE: BMY). From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. During his time at ATP, he was a board member of several companies, including Akero Therapeutics (Nasdaq: AKRO), Corvidia (acquired by Novo Nordisk), and Syntimmune (acquired by Alexion Pharmaceuticals, Inc. (formerly Nasdaq: ALXN)). Aaron received a B.S. in finance and international business from the New York University Leonard N. Stern School of Business.

Chair

Mitchell Chan

Mitchell Chan has more than 15 years of finance experience in the life sciences industry. Mr. Chan was previously the Chief Financial Officer at Viela Bio, where he was instrumental in supporting the company through capital raises with leading global healthcare investors. While at Viela Bio, he successfully raised over $750 million including an initial public offering in 2019. In 2021, he also led a merger transaction whereby Viela Bio was acquired by Horizon Therapeutics for $3.1 billion. Prior to Viela Bio, Mr. Chan served as the Director of Investor Relations for AstraZeneca, North America. Mr. Chan also held several roles of increasing responsibility at Genentech-Roche including in BioOncology Commercial Finance, R&D Finance, and Mergers & Acquisitions. Mr. Chan is the recipient of Executive Certifications from Stanford University, University of California (Haas), and University of Pennsylvania (Wharton) and earned his BSc in Biochemistry, MSc in Medical Biophysics, and MBA (Rotman School of Management) from the University of Toronto.

Member

Gilla Kaplan, PhD

Dr. Kaplan is recognized as an authority on various aspects of the host immune response to mycobacterial pathogens, including the causative agents of leprosy and tuberculosis. Most recently, she was the Director of the Global Health Tuberculosis program at the Bill & Melinda Gates Foundation (BMGF; January 2014 - April 2018). Her scientific work has encompassed developing a deep, holistic understanding of the cellular immune response and how to harness it for host adjunctive therapies. She spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease control. Building on her research experience at Rockefeller University in New York City (for 20 years) and then at the Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark (for 10 years), she led the reshaping of the TB program at the BMGF. Dr. Kaplan is the recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan served on the Board of Directors at Celgene from 1998 to 2018 and is currently a member of Tyra Biosciences, Inc.’s Board of Directors. Dr. Kaplan received her BSc from the Hebrew University in Jerusalem, Israel, and her MSc and PhD from Tromso University Norway. Dr. Kaplan was appointed as an independent director to the Avalo Board in October 2020.

Member

Samantha Truex

Samantha Truex is a seasoned biotech executive with almost 30 years of industry experience, including the last five years in CEO roles. Sam is on the board of Artios Pharma and has previously served on the boards of Hotspot Therapeutics, iPierian (acquired by Bristol Myers Squibb) and True North (acquired by Bioverativ Inc.). Sam was the founding CEO of Upstream Bio, the CEO of Quench Bio, COO of Synlogic and CBO for Padlock Therapeutics. Previously, Sam was Vice President of Corporate Development at Biogen Inc. (Nasdaq: BIIB) where she led transactional business development activities and served as program executive for now-marketed products FAMPYRA,® ELOCTATE™ and ALPROLIX™. Sam also previously worked in Corporate Development at Genzyme, Chiron Diagnostics and in consulting for Health Advances. Sam earned a BA in biology from Dartmouth College, a BE in biomedical engineering from the Thayer School at Dartmouth and an MBA from the Tuck School at Dartmouth. Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

Member

Compensation Committee Charter

Download

Aaron Kantoff

Aaron Kantoff is a founder and Managing Partner of Scion Life Sciences. He has spent over a decade specializing in founding, building and investing in biotech companies. Aaron was a founding board member of Tourmaline Bio (Nasdaq: TRML), Centessa Pharmaceuticals (Nasdaq: CNTA), and RayzeBio (Nasdaq: RYZB), which was recently acquired by Bristol Myers Squibb (NYSE: BMY). From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. During his time at ATP, he was a board member of several companies, including Akero Therapeutics (Nasdaq: AKRO), Corvidia (acquired by Novo Nordisk), and Syntimmune (acquired by Alexion Pharmaceuticals, Inc. (formerly Nasdaq: ALXN)). Aaron received a B.S. in finance and international business from the New York University Leonard N. Stern School of Business.

Mitchell Chan

Mitchell Chan has more than 15 years of finance experience in the life sciences industry. Mr. Chan was previously the Chief Financial Officer at Viela Bio, where he was instrumental in supporting the company through capital raises with leading global healthcare investors. While at Viela Bio, he successfully raised over $750 million including an initial public offering in 2019. In 2021, he also led a merger transaction whereby Viela Bio was acquired by Horizon Therapeutics for $3.1 billion. Prior to Viela Bio, Mr. Chan served as the Director of Investor Relations for AstraZeneca, North America. Mr. Chan also held several roles of increasing responsibility at Genentech-Roche including in BioOncology Commercial Finance, R&D Finance, and Mergers & Acquisitions. Mr. Chan is the recipient of Executive Certifications from Stanford University, University of California (Haas), and University of Pennsylvania (Wharton) and earned his BSc in Biochemistry, MSc in Medical Biophysics, and MBA (Rotman School of Management) from the University of Toronto.

Gilla Kaplan, PhD

Dr. Kaplan is recognized as an authority on various aspects of the host immune response to mycobacterial pathogens, including the causative agents of leprosy and tuberculosis. Most recently, she was the Director of the Global Health Tuberculosis program at the Bill & Melinda Gates Foundation (BMGF; January 2014 - April 2018). Her scientific work has encompassed developing a deep, holistic understanding of the cellular immune response and how to harness it for host adjunctive therapies. She spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease control. Building on her research experience at Rockefeller University in New York City (for 20 years) and then at the Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark (for 10 years), she led the reshaping of the TB program at the BMGF. Dr. Kaplan is the recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan served on the Board of Directors at Celgene from 1998 to 2018 and is currently a member of Tyra Biosciences, Inc.’s Board of Directors. Dr. Kaplan received her BSc from the Hebrew University in Jerusalem, Israel, and her MSc and PhD from Tromso University Norway. Dr. Kaplan was appointed as an independent director to the Avalo Board in October 2020.

Samantha Truex

Samantha Truex is a seasoned biotech executive with almost 30 years of industry experience, including the last five years in CEO roles. Sam is on the board of Artios Pharma and has previously served on the boards of Hotspot Therapeutics, iPierian (acquired by Bristol Myers Squibb) and True North (acquired by Bioverativ Inc.). Sam was the founding CEO of Upstream Bio, the CEO of Quench Bio, COO of Synlogic and CBO for Padlock Therapeutics. Previously, Sam was Vice President of Corporate Development at Biogen Inc. (Nasdaq: BIIB) where she led transactional business development activities and served as program executive for now-marketed products FAMPYRA,® ELOCTATE™ and ALPROLIX™. Sam also previously worked in Corporate Development at Genzyme, Chiron Diagnostics and in consulting for Health Advances. Sam earned a BA in biology from Dartmouth College, a BE in biomedical engineering from the Thayer School at Dartmouth and an MBA from the Tuck School at Dartmouth. Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

Nominating and Corporate Governance Committee Position

Samantha Truex

Samantha Truex is a seasoned biotech executive with almost 30 years of industry experience, including the last five years in CEO roles. Sam is on the board of Artios Pharma and has previously served on the boards of Hotspot Therapeutics, iPierian (acquired by Bristol Myers Squibb) and True North (acquired by Bioverativ Inc.). Sam was the founding CEO of Upstream Bio, the CEO of Quench Bio, COO of Synlogic and CBO for Padlock Therapeutics. Previously, Sam was Vice President of Corporate Development at Biogen Inc. (Nasdaq: BIIB) where she led transactional business development activities and served as program executive for now-marketed products FAMPYRA,® ELOCTATE™ and ALPROLIX™. Sam also previously worked in Corporate Development at Genzyme, Chiron Diagnostics and in consulting for Health Advances. Sam earned a BA in biology from Dartmouth College, a BE in biomedical engineering from the Thayer School at Dartmouth and an MBA from the Tuck School at Dartmouth. Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

Chair

Aaron Kantoff

Aaron Kantoff is a founder and Managing Partner of Scion Life Sciences. He has spent over a decade specializing in founding, building and investing in biotech companies. Aaron was a founding board member of Tourmaline Bio (Nasdaq: TRML), Centessa Pharmaceuticals (Nasdaq: CNTA), and RayzeBio (Nasdaq: RYZB), which was recently acquired by Bristol Myers Squibb (NYSE: BMY). From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. During his time at ATP, he was a board member of several companies, including Akero Therapeutics (Nasdaq: AKRO), Corvidia (acquired by Novo Nordisk), and Syntimmune (acquired by Alexion Pharmaceuticals, Inc. (formerly Nasdaq: ALXN)). Aaron received a B.S. in finance and international business from the New York University Leonard N. Stern School of Business.

Member

Gilla Kaplan, PhD

Dr. Kaplan is recognized as an authority on various aspects of the host immune response to mycobacterial pathogens, including the causative agents of leprosy and tuberculosis. Most recently, she was the Director of the Global Health Tuberculosis program at the Bill & Melinda Gates Foundation (BMGF; January 2014 - April 2018). Her scientific work has encompassed developing a deep, holistic understanding of the cellular immune response and how to harness it for host adjunctive therapies. She spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease control. Building on her research experience at Rockefeller University in New York City (for 20 years) and then at the Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark (for 10 years), she led the reshaping of the TB program at the BMGF. Dr. Kaplan is the recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan served on the Board of Directors at Celgene from 1998 to 2018 and is currently a member of Tyra Biosciences, Inc.’s Board of Directors. Dr. Kaplan received her BSc from the Hebrew University in Jerusalem, Israel, and her MSc and PhD from Tromso University Norway. Dr. Kaplan was appointed as an independent director to the Avalo Board in October 2020.

Member

Nominating and Corporate Governance Committee Charter

Download

Samantha Truex

Samantha Truex is a seasoned biotech executive with almost 30 years of industry experience, including the last five years in CEO roles. Sam is on the board of Artios Pharma and has previously served on the boards of Hotspot Therapeutics, iPierian (acquired by Bristol Myers Squibb) and True North (acquired by Bioverativ Inc.). Sam was the founding CEO of Upstream Bio, the CEO of Quench Bio, COO of Synlogic and CBO for Padlock Therapeutics. Previously, Sam was Vice President of Corporate Development at Biogen Inc. (Nasdaq: BIIB) where she led transactional business development activities and served as program executive for now-marketed products FAMPYRA,® ELOCTATE™ and ALPROLIX™. Sam also previously worked in Corporate Development at Genzyme, Chiron Diagnostics and in consulting for Health Advances. Sam earned a BA in biology from Dartmouth College, a BE in biomedical engineering from the Thayer School at Dartmouth and an MBA from the Tuck School at Dartmouth. Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

Aaron Kantoff

Aaron Kantoff is a founder and Managing Partner of Scion Life Sciences. He has spent over a decade specializing in founding, building and investing in biotech companies. Aaron was a founding board member of Tourmaline Bio (Nasdaq: TRML), Centessa Pharmaceuticals (Nasdaq: CNTA), and RayzeBio (Nasdaq: RYZB), which was recently acquired by Bristol Myers Squibb (NYSE: BMY). From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. During his time at ATP, he was a board member of several companies, including Akero Therapeutics (Nasdaq: AKRO), Corvidia (acquired by Novo Nordisk), and Syntimmune (acquired by Alexion Pharmaceuticals, Inc. (formerly Nasdaq: ALXN)). Aaron received a B.S. in finance and international business from the New York University Leonard N. Stern School of Business.

Gilla Kaplan, PhD

Dr. Kaplan is recognized as an authority on various aspects of the host immune response to mycobacterial pathogens, including the causative agents of leprosy and tuberculosis. Most recently, she was the Director of the Global Health Tuberculosis program at the Bill & Melinda Gates Foundation (BMGF; January 2014 - April 2018). Her scientific work has encompassed developing a deep, holistic understanding of the cellular immune response and how to harness it for host adjunctive therapies. She spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease control. Building on her research experience at Rockefeller University in New York City (for 20 years) and then at the Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark (for 10 years), she led the reshaping of the TB program at the BMGF. Dr. Kaplan is the recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan served on the Board of Directors at Celgene from 1998 to 2018 and is currently a member of Tyra Biosciences, Inc.’s Board of Directors. Dr. Kaplan received her BSc from the Hebrew University in Jerusalem, Israel, and her MSc and PhD from Tromso University Norway. Dr. Kaplan was appointed as an independent director to the Avalo Board in October 2020.

Science and Technology Committee Position

Gilla Kaplan, PhD

Dr. Kaplan is recognized as an authority on various aspects of the host immune response to mycobacterial pathogens, including the causative agents of leprosy and tuberculosis. Most recently, she was the Director of the Global Health Tuberculosis program at the Bill & Melinda Gates Foundation (BMGF; January 2014 - April 2018). Her scientific work has encompassed developing a deep, holistic understanding of the cellular immune response and how to harness it for host adjunctive therapies. She spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease control. Building on her research experience at Rockefeller University in New York City (for 20 years) and then at the Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark (for 10 years), she led the reshaping of the TB program at the BMGF. Dr. Kaplan is the recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan served on the Board of Directors at Celgene from 1998 to 2018 and is currently a member of Tyra Biosciences, Inc.’s Board of Directors. Dr. Kaplan received her BSc from the Hebrew University in Jerusalem, Israel, and her MSc and PhD from Tromso University Norway. Dr. Kaplan was appointed as an independent director to the Avalo Board in October 2020.

Chair

June Almenoff, MD, PhD

June Almenoff M.D., Ph.D., is an accomplished biopharma executive with close to 25 years of leadership experience. She brings expertise in R&D, commercialization, and executive leadership to this role. Dr. Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, which was acquired by Actavis for $1.2B. Furiex developed eluxadoline (Viberzi®), which was approved both in the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility.

Dr. Almenoff also served as Chief Medical Officer at RedHill Biopharma Ltd (Nasdaq: RDHL), where she was on the commercial executive team. She has deep expertise in many therapeutic and development areas having led or contributed to numerous submissions, product approvals and launches. Dr. Almenoff is on the investment advisory board of the Harrington Discovery Institute, a private venture philanthropy. She serves as a Board Director to Tenax Therapeutics, Inc. (Nasdaq: TENX). She previously served as a Board Director to Tigenix, which was acquired by Takeda, Kurome Therapeutics,  Brainstorm Cell Therapeutics (Nasdaq: BCLI), RDD Pharma (Chair), and Furiex Pharmaceuticals. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct Professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over 70 publications.

Member

Jonathan Goldman, MD

Jonathan Goldman, MD has 30 years of experience across life sciences as a CEO, Chief Medical Officer, investor, and senior executive. He currently serves as the CEO of Clinical ink, a global life science company that brings data, technology, and patient-centric research together. Prior to Clinical ink, Jonathan served as the CEO and a board member of Abzena and was previously the CEO of Aptuit. He has also held senior executive positions at ICON plc (Nasdaq: ICLR) and Point Biomedical Corp. in addition to holding appointments as Associate Clinical Professor of Medicine in the division of Cardiology at the University of California San Francisco, and as an Attending Cardiologist at the San Francisco Veterans Administration Medical Center. Jonathan trained in medicine at St. Bartholomew’s Hospital Medical College, in London and in cardiology at St. George’s Hospital Medical School, London. He received a BSc in immunology, as well as MBBS and MD degrees in medicine from the University of London, UK. He was awarded MBAs by Columbia University in New York and the University of California at Berkeley.

Member

Science and Technology Committee Charter

Download

Gilla Kaplan, PhD

Dr. Kaplan is recognized as an authority on various aspects of the host immune response to mycobacterial pathogens, including the causative agents of leprosy and tuberculosis. Most recently, she was the Director of the Global Health Tuberculosis program at the Bill & Melinda Gates Foundation (BMGF; January 2014 - April 2018). Her scientific work has encompassed developing a deep, holistic understanding of the cellular immune response and how to harness it for host adjunctive therapies. She spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease control. Building on her research experience at Rockefeller University in New York City (for 20 years) and then at the Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark (for 10 years), she led the reshaping of the TB program at the BMGF. Dr. Kaplan is the recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan served on the Board of Directors at Celgene from 1998 to 2018 and is currently a member of Tyra Biosciences, Inc.’s Board of Directors. Dr. Kaplan received her BSc from the Hebrew University in Jerusalem, Israel, and her MSc and PhD from Tromso University Norway. Dr. Kaplan was appointed as an independent director to the Avalo Board in October 2020.

June Almenoff, MD, PhD

June Almenoff M.D., Ph.D., is an accomplished biopharma executive with close to 25 years of leadership experience. She brings expertise in R&D, commercialization, and executive leadership to this role. Dr. Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, which was acquired by Actavis for $1.2B. Furiex developed eluxadoline (Viberzi®), which was approved both in the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility.

Dr. Almenoff also served as Chief Medical Officer at RedHill Biopharma Ltd (Nasdaq: RDHL), where she was on the commercial executive team. She has deep expertise in many therapeutic and development areas having led or contributed to numerous submissions, product approvals and launches. Dr. Almenoff is on the investment advisory board of the Harrington Discovery Institute, a private venture philanthropy. She serves as a Board Director to Tenax Therapeutics, Inc. (Nasdaq: TENX). She previously served as a Board Director to Tigenix, which was acquired by Takeda, Kurome Therapeutics,  Brainstorm Cell Therapeutics (Nasdaq: BCLI), RDD Pharma (Chair), and Furiex Pharmaceuticals. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct Professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over 70 publications.

Jonathan Goldman, MD

Jonathan Goldman, MD has 30 years of experience across life sciences as a CEO, Chief Medical Officer, investor, and senior executive. He currently serves as the CEO of Clinical ink, a global life science company that brings data, technology, and patient-centric research together. Prior to Clinical ink, Jonathan served as the CEO and a board member of Abzena and was previously the CEO of Aptuit. He has also held senior executive positions at ICON plc (Nasdaq: ICLR) and Point Biomedical Corp. in addition to holding appointments as Associate Clinical Professor of Medicine in the division of Cardiology at the University of California San Francisco, and as an Attending Cardiologist at the San Francisco Veterans Administration Medical Center. Jonathan trained in medicine at St. Bartholomew’s Hospital Medical College, in London and in cardiology at St. George’s Hospital Medical School, London. He received a BSc in immunology, as well as MBBS and MD degrees in medicine from the University of London, UK. He was awarded MBAs by Columbia University in New York and the University of California at Berkeley.